Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Michael C. Cameron"'
Autor:
Nina Magnolo, Michael C. Cameron, Mona Shahriari, Bob Geng, Brian M. Calimlim, Henrique Teixeira, Xiaofei Hu, Yang Yang, Yingyi Liu, Shiyu Zhang, Cristina Sancho Sanchez, Katherine Altman, Richard G. Langley
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
AbstractPurpose: Atopic dermatitis (AD) adversely impacts quality of life (QoL). We evaluated the effect of upadacitinib, an oral selective Janus kinase inhibitor approved for moderate-to-severe AD, plus topical corticosteroids (+TCS) on patient-repo
Externí odkaz:
https://doaj.org/article/e139efa252da462c88ff16c82b4fb9cd
Autor:
Seemal R. Desai, Linda Stein Gold, Michael C. Cameron, Alexandra Golant, G. Michael Lewitt, Matthew J. Bruno, George Martin, Philip M. Brown, David S. Rubenstein, Victoria Butners, Anna M. Tallman
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 10, Pp 2443-2460 (2023)
Abstract Tapinarof cream 1% (VTAMA®; Dermavant Sciences, Inc.) is a non-steroidal, topical, aryl hydrocarbon receptor agonist approved by the US Food and Drug Administration (FDA) to treat plaque psoriasis in adults and under investigation for the t
Externí odkaz:
https://doaj.org/article/765499add9ea47908d1b15a7a34f1ce3
Autor:
Melinda J. Gooderham, MSc, MD, FRCPC, Chia-Yu Chu, MD, PhD, Ricardo Rojo, MD, Hernan Valdez, MD, Pinaki Biswas, PhD, Michael C. Cameron, MD, Claire Feeney, MD, PhD, Gerardo A. Encinas, MD, MHS, Kathleen Peeples-Lamirande, PharmD, MPH, Joseph C. Cappelleri, PhD, Daniela E. Myers, MPH, Marco DiBonaventura, PhD
Publikováno v:
JAAD International, Vol 4, Iss , Pp 46-48 (2021)
Externí odkaz:
https://doaj.org/article/13593df58a0348208ccd60f8f06ab9a3
Autor:
Vivian Y, Shi, Tina, Bhutani, Luz, Fonacier, Mette, Deleuran, Stephen, Shumack, Hernan, Valdez, Fan, Zhang, Gary L, Chan, Michael C, Cameron, Natalie C, Yin
Publikováno v:
Shi, V Y, Bhutani, T, Fonacier, L, Deleuran, M, Shumack, S, Valdez, H, Zhang, F, Chan, G L, Cameron, M C & Yin, N C 2022, ' Phase 3 Efficacy and Safety of Abrocitinib in Adults with Moderate-to-Severe Atopic Dermatitis After Switching from Dupilumab (JADE EXTEND) ', Journal of the American Academy of Dermatology, vol. 87, no. 2, pp. 351-358 . https://doi.org/10.1016/j.jaad.2022.04.009
BACKGROUND: Abrocitinib efficacy by prior dupilumab response status in patients with moderate-to-severe atopic dermatitis (AD) has not previously been assessed in phase 3 studies.OBJECTIVE: Examine efficacy and safety of abrocitinib among patients wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9a7a61a7bb21623cbeb8dbaf42cf563
https://doi.org/10.1016/j.jaad.2022.04.009
https://doi.org/10.1016/j.jaad.2022.04.009
Autor:
Urs Kerkmann, Marco DiBonaventura, Sonja Ständer, Michael C. Cameron, Eric L. Simpson, Saleem A. Farooqui, Brian S. Kim, Gil Yosipovitch, Jonathan I. Silverberg, Hernan Valdez, Pinaki Biswas
Publikováno v:
Dermatitis
Supplemental digital content is available in the text.
Background Itch, the most bothersome symptom in atopic dermatitis, is largely mediated by pruritogenic cytokines via Janus kinase 1 signaling in cutaneous sensory neurons. Objectives The aim
Background Itch, the most bothersome symptom in atopic dermatitis, is largely mediated by pruritogenic cytokines via Janus kinase 1 signaling in cutaneous sensory neurons. Objectives The aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9d017f7f4230739ffd81e473c5f8422
https://doi.org/10.1097/der.0000000000000770
https://doi.org/10.1097/der.0000000000000770
Autor:
Daniela E. Myers, Jacob P. Thyssen, Joseph C. Cappelleri, Claire Clibborn, K Mickle, Michael C. Cameron, Marco DiBonaventura, Kyle Fahrbach, Jonathan I. Silverberg, William Romero
Publikováno v:
Journal of the European Academy of Dermatology and Venereology
Given the lack of head‐to‐head studies of systemic therapies in moderate‐to‐severe atopic dermatitis (AD), network meta‐analyses (NMAs) can provide comparative efficacy and safety data to inform clinical decision‐making. In this NMA, elig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef9d48f56db071b117416ebb2453d0d1
https://doi.org/10.1111/jdv.17351
https://doi.org/10.1111/jdv.17351
Autor:
Sonja, Ständer, Shawn G, Kwatra, Jonathan I, Silverberg, Eric L, Simpson, Jacob P, Thyssen, Gil, Yosipovitch, Fan, Zhang, Michael C, Cameron, Ricardo Rojo, Cella, Hernan, Valdez, Marco, DiBonaventura, Claire, Feeney
Publikováno v:
American journal of clinical dermatology.
Abrocitinib, an oral Janus kinase 1 inhibitor, provided significant itch relief by week 2 in patients with moderate-to-severe atopic dermatitis (AD) in the phase III JADE COMPARE trial.This post-hoc analysis of JADE COMPARE aimed to further character
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7e3af33b1ee99a5d2bd83f090c51d43e
https://pubmed.ncbi.nlm.nih.gov/36512175
https://pubmed.ncbi.nlm.nih.gov/36512175
Autor:
Andrew Blauvelt, Mark Boguniewicz, Patrick M. Brunner, Paula C. Luna, Pinaki Biswas, Marco DiBonaventura, Saleem A. Farooqui, Ricardo Rojo, Michael C. Cameron
Publikováno v:
The Journal of dermatological treatment. 33(5)
Abrocitinib, a once-daily, oral Janus kinase 1 selective inhibitor, was shown to be an effective treatment for moderate-to-severe atopic dermatitis in phase 2 b/3 monotherapy trials. These analyses included data for Investigator’s Global Assessment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d9b5e9a0739aa373ee48b28e0090875
https://pubmed.ncbi.nlm.nih.gov/35763326
https://pubmed.ncbi.nlm.nih.gov/35763326
Autor:
Vivian Shi, Tina Bhutani, Mette Deleuran, Luz Fonacier, Stephen Shumack, Fan Zhang, Michael C. Cameron, Gary L. Chan, Hernan Valdez, Natalie Yin
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 7:s153
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f111d7b91ec47d3f732dc9260f5bb5fd
https://doi.org/10.25251/skin.7.supp.153
https://doi.org/10.25251/skin.7.supp.153
Autor:
Pinaki Biswas, Melinda Gooderham, Daniela E. Myers, Chia-Yu Chu, Claire Feeney, Ricardo Rojo, Hernan Valdez, Marco DiBonaventura, Gerardo A. Encinas, Michael C. Cameron, Joseph C. Cappelleri, Kathleen Peeples-Lamirande
Publikováno v:
JAAD International, Vol 4, Iss, Pp 46-48 (2021)
JAAD International
JAAD International
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ad03bd0f83a2ff79e440f0633bfca01
http://www.sciencedirect.com/science/article/pii/S2666328721000341
http://www.sciencedirect.com/science/article/pii/S2666328721000341